Squirrels in space? Fauna Bio snags NASA grant to study hibernation in orbit

Microgravity laboratory will allow the protective effects of hibernation to be assessed in the International Space Station.
Longevity biotech Fauna Bio announced today that one of its researchers has been awarded a NASA Innovative Advanced Concepts (NIAC) grant to…Read More

Calluna Pharma launches with €75m to target inflammatory and fibrotic diseases

New European biopharma company emerges from Oxitope and Arxx merger with a pipeline of antibodies targeting immunological diseases.
Formed by the merger of biotech companies Oxitope Pharma and Arxx Therapeutics, new European biotech Calluna Pharma has emerged, s…Read More

Vesper Bio bags Michael J Fox Foundation grant to assess sortilin inhibitor impact in Parkinson’s

Targeting sortilin to rebalance progranulin levels thought to hold promise in CNS diseases, including Parkinson’s.
Danish biotech Vesper Bio revealed it has been awarded a grant worth approximately $873,000 by The Michael J Fox Foundation for Par…Read More

Juvena gets FDA Orphan Drug nod for muscle regeneration therapy

Longevity biotech goes after rare muscle disease with plans to expand into diseases of aging, including sarcopenia.
Longevity biotech startup Juvena Therapeutics has been granted the FDA’s Orphan Drug designation for using its flagship drug candidate, JUV-161, to address M…Read More

‘Skinny jabs’ may be longevity drugs, but healthy people shouldn’t be taking them
Leading GLP-1 researcher says while drugs like semaglutide do appear to have longevity benefits, they won’t make healthy people healthier.
Semaglutide, the so called “skinny jab”, marketed around the world as Wegovy, Ozempic and Rybelsus, is rarely out of the news…Read More